Premium
Opportunities, controversies, and challenges of extracorporeal hemoadsorption with CytoSorb during ECMO
Author(s) -
Napp L. Christian,
Lebreton Guillaume,
De Somer Filip,
Supady Alexander,
Pappalardo Federico
Publication year - 2021
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/aor.14025
Subject(s) - medicine , extracorporeal membrane oxygenation , intensive care medicine , extracorporeal , extracorporeal circulation , clinical trial , randomized controlled trial , surgery
Extracorporeal membrane oxygenation (ECMO) is frequently used in many centers around the globe for various indications. However, prognosis is often poor even with all supportive therapies, and in many cases, clinical deterioration is associated with inflammation. Hemoadsorption with CytoSorb is a novel approach to limit the inflammatory response, and the device can be safely and easily installed into ECMO circuits. CytoSorb has been used more than 130.000 times to date, but because randomized controlled trials are largely lacking, there is substantial debate on its use. Here, experts from critical care medicine, cardiology, cardiac surgery, and perfusion technology discuss the pros and cons of this novel therapy and outline the future aspects for its clinical application and research.